13.1 Acute Respiratory Distress Syndrome (ARDS) in Trauma

13.1 Acute Respiratory Distress Syndrome (ARDS) in Trauma

Clinical Summary: Acute Respiratory Distress Syndrome (ARDS) is a devastating inflammatory lung injury triggered by direct thoracic trauma or systemic inflammatory insults. Management centers on early recognition via Berlin criteria, lung-protective mechanical ventilation with low tidal volumes (4-8 mL/kg predicted body weight), plateau pressure restriction (< 30 cmH2O), recruitment via PEEP, and rescue prone positioning.

Acute Respiratory Distress Syndrome (ARDS) represents one of the most severe pulmonary complications encountered in post-resuscitation trauma critical care. Characterized by diffuse alveolar damage, alveolar-capillary membrane disruption, non-cardiogenic pulmonary edema, and profound hypoxemia, ARDS develops in up to 25% of critically injured trauma patients. Recognizing the clinical drivers, diagnostic parameters, and lung-protective ventilation strategies is essential for the Trauma Certified Registered Nurse (TCRN).

---

Etiology and Pathophysiology in the Trauma Patient

ARDS in trauma results from either direct (primary pulmonary) or indirect (secondary systemic) pulmonary insults. Direct trauma causes direct structural disruption of pulmonary tissue, whereas indirect insults induce a systemic inflammatory cascade that damages the alveolar-capillary unit secondarily.

The Inflammatory Cascade

The pathophysiologic progression of ARDS occurs across three distinct phases:

1. Exudative Phase (Days 1–7): Damaged vascular endothelium and alveolar epithelium allow protein-rich fluid to leak into the interstitial and alveolar spaces. Neutrophils infiltrate the pulmonary parenchyma, releasing reactive oxygen species, proteases, and pro-inflammatory cytokines. Surfactant inactivation causes widespread alveolar collapse (microatelectasis), resulting in severe ventilation-perfusion (V/Q) mismatching and intrapulmonary shunting. Fibrin and cellular debris form hyaline membranes along alveolar walls.
2. Proliferative Phase (Days 7–21): Fibroblasts proliferate within the alveolar interstitium. Type II pneumocytes attempt to regenerate alveolar epithelium, but persistent inflammation leads to progressive alveolar thickening and reduced pulmonary compliance.
3. Fibrotic Phase (Day 21+): Extensive remodeling leads to irreversible pulmonary fibrosis, loss of vascular bed area, and chronic pulmonary hypertension.

---

Diagnostic Criteria: The Berlin Definition

ARDS diagnosis is established using the international Berlin Definition criteria. The trauma nurse must verify that all four diagnostic components are met:

Berlin ARDS Diagnostic Criteria:
├── Timing: Within 1 week of a known clinical insult or new/worsening respiratory symptoms
├── Chest Imaging: Bilateral opacities on chest radiograph or CT scan (not fully explained by effusions, collapse, or nodules)
├── Origin of Edema: Respiratory failure not fully explained by cardiac failure or fluid overload (objective assessment e.g., echocardiogram required if no risk factor present)
└── Oxygenation Impairment (with PEEP or CPAP ≥ 5 cmH2O):
    ├── Mild ARDS:     200 mmHg < PaO2/FiO2 ≤ 300 mmHg
    ├── Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg
    └── Severe ARDS:   PaO2/FiO2 ≤ 100 mmHg

Note on Calculation: The $PaO_2/FiO_2$ (P/F) ratio is calculated by dividing arterial oxygen tension ($PaO_2$ in mmHg) by the fractional inspired oxygen ($FiO_2$ expressed as a decimal). For example, a patient on $FiO_2$ 0.60 (60%) with a $PaO_2$ of 90 mmHg has a P/F ratio of $90 / 0.60 = 150 \text{ mmHg}$ (Moderate ARDS).

---

Mechanical Ventilation & Lung-Protective Strategies

Standard ventilation practices with high tidal volumes exacerbate lung injury through volutrauma (overdistension), barotrauma (excessive airway pressures), and atelectrauma (repetitive alveolar opening and collapse). The cornerstone of ARDS management is Low Tidal Volume Ventilation (LTVV) based on the landmark ARDSNet protocol.

Low Tidal Volume Protocol (ARDSNet)

• Predicted Body Weight (PBW): Tidal volume ($V_t$) must be calculated using Predicted Body Weight (PBW) based on patient height and biological sex—never actual body weight. Actual weight reflects adipose tissue and fluid accumulation, whereas adult lung volume is determined purely by height and sex.
  • Male PBW (kg): $50 + 0.91 \times (\text{height in cm} - 152.4)$
  • Female PBW (kg): $45.5 + 0.91 \times (\text{height in cm} - 152.4)$
• Initial Setting: Initiate ventilation at $6 \text{ mL/kg PBW}$, titrating down by $1 \text{ mL/kg}$ decrements every 2 hours to a minimum of $4 \text{ mL/kg PBW}$ if necessary to maintain target airway pressures.
• Plateau Pressure ($P_{plat}$) Target: Measure end-inspiratory pause pressure ($P_{plat}$). Maintain $P_{plat} \le 30 \text{ cmH}_2\text{O}$. Elevated plateau pressure correlates directly with alveolar overdistension and barotrauma.
• Driving Pressure ($\Delta P$): Calculated as $\Delta P = P_{plat} - PEEP$. Targeting a driving pressure $< 14\text{--}15 \text{ cmH}_2\text{O}$ optimizes dynamic compliance and reduces mortality.

Permissive Hypercapnia

Reducing tidal volumes frequently results in hypercapnic respiratory acidosis. Permissive hypercapnia is accepted to protect the lungs, allowing arterial $PaCO_2$ to rise (typically $45\text{--}65 \text{ mmHg}$) provided systemic pH is maintained $\ge 7.20\text{--}7.25$. Critical Exception: Permissive hypercapnia is strictly contraindicated in patients with co-existing Traumatic Brain Injury (TBI) and elevated Intracranial Pressure (ICP). Elevated $PaCO_2$ causes cerebral vasodilation, increasing cerebral blood volume and precipitously raising ICP.

PEEP Titration & Alveolar Recruitment

Positive End-Expiratory Pressure (PEEP) maintains alveolar patency at end-expiration, preventing atelectrauma and expanding functional residual capacity (FRC). Higher PEEP ($10\text{--}20 \text{ cmH}_2\text{O}$) is titrated using high-PEEP/lower-$FiO_2$ tables to achieve arterial oxygenation goals ($PaO_2$ $55\text{--}80 \text{ mmHg}$ or $SpO_2$ 88–95%) while avoiding cardiac preload compromise.

---

Rescue Therapies for Severe ARDS

When mechanical ventilation alone fails to achieve adequate oxygenation ($P/F \le 150 \text{ mmHg}$), advanced evidence-based rescue interventions are implemented:

1. Prone Positioning

Prone positioning is recommended for patients with severe ARDS ($P/F < 150 \text{ mmHg}$ with $PEEP \ge 10 \text{ cmH}_2\text{O}$) for at least 16 consecutive hours per day (PROSEVA trial protocol).

• Physiological Rationale: Placed prone, ventral pulmonary segments become dependent, while dorsal lung regions are relieved of cardiac and abdominal compression. This redistributes perfusion toward better-ventilated alveoli, dramatically improving V/Q matching and recruiting atelectatic dorsal lung units.
• Nursing Care: Secure endotracheal tube, central lines, and invasive monitoring prior to turns. Utilize specialized rotating beds or manual multi-person turn teams. Monitor pressure points (face, chest, knees, pelvis) to prevent skin breakdown.

2. Neuromuscular Blockade (NMB)

Early continuous infusion of neuromuscular blocking agents (e.g., cisatracurium) for 24–48 hours in severe ARDS reduces patient-ventilator dyssynchrony, lowers oxygen consumption, and eliminates chest wall resistance. Adequate deep sedation must always precede paralysis.

3. Inhaled Pulmonary Vasodilators

Inhaled Epoprostenol (prostacyclin) or Inhaled Nitric Oxide (iNO) selective vasodilates microvascular beds in ventilated lung units, shunting blood away from non-ventilated areas to improve P/F ratio without causing systemic hypotension.

4. Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

For refractory hypoxemic respiratory failure ($P/F < 80 \text{ mmHg}$ despite optimal LTVV, prone positioning, and NMB), VV-ECMO provides complete extracorporeal gas exchange, permitting ultra-lung-protective ventilation ($V_t$ 2–3 mL/kg, low driving pressure) to allow pulmonary healing.